A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a ...
Apr 20, 2026
0
3
A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer when given as ...
Apr 13, 2026
0
6
Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory ...
Apr 8, 2026
0
9
Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for only about 20% of patients, though, and doctors still struggle to predict who will benefit.
Apr 1, 2026
0
4
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing ...
Mar 25, 2026
0
562
A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found that Programmed Death-Ligand ...
Mar 18, 2026
0
10
A research team led by Professor Ki-Young Lee at the College of Medicine, Sungkyunkwan University, has uncovered a previously unrecognized tumor-intrinsic role of the immune checkpoint molecule PD-L1, providing new mechanistic ...
Feb 26, 2026
0
3
Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do not trigger especially ...
Feb 11, 2026
0
10
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced durable responses in ...
Jan 28, 2026
0
59
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
14
